An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
Authors:
- V MartinVMV Martin
- L MazzucchelliLML Mazzucchelli
- M FrattiniMFM Frattini
- 3 December 2008
- journal article
- review article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 62 (4) , 314-324
Abstract
Epidermal growth factor receptor (EGFR) is deregulated in a variety of solid malignant tumours. Due to the availability of specific targeted therapies, the request to evaluate EGFR in neoplastic tissues in pathology is dramatically increasing. In analogy to HER2, EGFR evaluation by FISH seems to be superior than immunohistochemistry to select patients for targeted therapies. However, the lack of consensus on how to assess the presence and extent of EGFR gene status deregulation in tissue sections has generated a confusion of inadequately defined criteria, which impairs the quality of communication in both routine patient care and research studies. The objectives of this review are: (1) to analyse methodological aspects, signals evaluation and interpretation criteria related to the detection of EGFR alterations by FISH in cancer samples, highlighting technical limits and controversies; (2) to review the literature concerning EGFR FISH on formalin-fixed paraffin-embedded tissue sections from different types of solid tumours, with a particular focus on the clinical significance of numerical EGFR gene alterations with respect to targeted therapies. Further advances in improving the quality of care of patients with cancers characterised by EGFR gene deregulation will depend on answering some of the questions underlined throughout this overview.Keywords
This publication has 77 references indexed in Scilit:
- Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysisThe Prostate, 2008
- Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinomaCancer, 2007
- Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx™ in paraffin-embedded cancer tissuesPathology and Oncology Research, 2006
- Prognostic stratification of patients with anaplastic gliomas according to genetic profileCancer, 2006
- Prognostic impact of molecular markers in a series of 220 primary glioblastomasCancer, 2006
- Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinomaJournal of Molecular Medicine, 2006
- Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma☆Human Pathology, 2006
- The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 yearsCancer, 2005
- Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynxJournal of Cancer Research and Clinical Oncology, 2004
- Epidermal growth factor receptor: a promising target in solid tumoursCancer Treatment Reviews, 2004